> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Teva Used Priority Voucher for Migraine Drug
- URL: https://www.fdaweb.com/teva-used-priority-voucher-for-migraine-drug/
- Published: 2018-11-21T12:00:00.000Z
- Updated: 2026-09-15T00:46:23.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5142875

*Federal Register* notice: FDA has announced an approval for Teva’s Ajovy (fremanezumab-vfrm) injection for preventing migraine in adults under a redeemed priority review voucher. Such vouchers are awarded to sponsors of approved rare pediatric disease product applications that meet certain criteria. The agency is required to publish notice of the issuance of vouchers as well as the approval of products redeeming a voucher. To view the notice, click [here](https://s3.amazonaws.com/public-inspection.federalregister.gov/2018-25480.pdf?ref=fdaweb.com).